Avidity Biosciences (RNA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

RNA Stock Forecast

Avidity Biosciences stock forecast is as follows: an average price target of $59.00 (represents a 85.42% upside from RNA’s last price of $31.82) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

RNA Price Target

The average price target for Avidity Biosciences (RNA) is $59.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $59.00 to $59.00. This represents a potential 85.42% upside from RNA's last price of $31.82.

RNA Analyst Ratings

Buy

According to 8 Wall Street analysts, Avidity Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for RNA stock is 1 'Strong Buy' (12.50%), 7 'Buy' (87.50%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Avidity Biosciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 24, 2024	Corinne Johnson	Goldman Sachs	$59.00	$43.50	35.63%	85.42%
Jun 12, 2024	Yanan Zhu	Wells Fargo	$50.00	$28.92	72.89%	57.13%

The latest Avidity Biosciences stock forecast, released on Sep 24, 2024 by Corinne Johnson from Goldman Sachs, set a price target of $59.00, which represents a 35.63% increase from the stock price at the time of the forecast ($43.50), and a 85.42% increase from RNA last price ($31.82).

Avidity Biosciences Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	2
Avg Price Target	-	$59.00	$54.50
Last Closing Price	$31.82	$31.82	$31.82
Upside/Downside	-100.00%	85.42%	71.28%

In the current month, the average price target of Avidity Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Avidity Biosciences's last price of $31.82. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 30, 2024	Goldman Sachs	Buy	Buy	Hold
Oct 21, 2024	Needham	Buy	Buy	Hold
Oct 21, 2024	Goldman Sachs	Underperform	Underperform	Hold
Oct 21, 2024	Cowen & Co.	Buy	Buy	Hold
Oct 03, 2024	Goldman Sachs	Buy	Buy	Hold
Sep 24, 2024	Goldman Sachs		Buy	Initialise
Sep 16, 2024	Evercore Partners	Underperform	Underperform	Hold
Sep 16, 2024	Needham	Buy	Buy	Hold
Aug 28, 2024	Barclays		Overweight	Initialise
Aug 12, 2024	Needham	Buy	Buy	Hold
Aug 12, 2024	Evercore Partners	Underperform	Underperform	Hold
Jun 25, 2024	Cowen & Co.	Buy	Buy	Hold
Jun 13, 2024	Bank of America Securities	Buy	Buy	Hold
Jun 12, 2024	Evercore ISI	Outperform	Outperform	Hold
Jun 12, 2024	Wells Fargo	Overweight	Overweight	Hold
Jun 10, 2024	Needham	Buy	Buy	Hold
May 03, 2024	Needham	Buy	Buy	Hold
May 03, 2024	Chardan Capital	Underperform	Underperform	Hold
Mar 14, 2024	Cantor Fitzgerald		Accumulate	Initialise
Mar 05, 2024	Chardan Capital	Buy	Buy	Hold
Mar 05, 2024	Wells Fargo	Buy	Buy	Hold
May 22, 2023	Evercore ISI		Outperform	Upgrade
Jul 12, 2022	Raymond James		Strong Buy	Initialise

Avidity Biosciences's last stock rating was published by Goldman Sachs on Oct 30, 2024. The company gave RNA a "Buy" rating, the same as its previous rate.

Avidity Biosciences Financial Forecast

Avidity Biosciences Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.82M	$2.32M	$2.23M	$2.77M	$2.48M	$2.18M	$1.79M	$1.85M	$2.16M	$2.61M	$2.70M	$2.14M	$1.75M	$1.54M
Avg Forecast	$4.59M	$4.26M	$3.95M	$3.66M	$1.67M	$1.63M	$1.63M	$1.63M	$1.55M	$4.07M	$2.63M	$2.57M	$12.21M	$2.21M	$2.14M	$2.04M	$2.16M	$2.13M	$2.11M	$1.90M	$2.17M	$2.13M	$1.94M	$1.00M	$838.75K	$575.00K	$700.00K
High Forecast	$4.59M	$4.26M	$3.95M	$3.66M	$1.67M	$1.63M	$1.63M	$1.63M	$1.55M	$4.20M	$2.63M	$2.57M	$23.86M	$2.21M	$2.14M	$2.04M	$2.16M	$2.13M	$2.11M	$1.90M	$2.17M	$2.13M	$1.94M	$1.00M	$838.75K	$575.00K	$700.00K
Low Forecast	$4.59M	$4.26M	$3.95M	$3.66M	$1.67M	$1.63M	$1.63M	$1.63M	$1.55M	$3.94M	$2.63M	$2.57M	$570.98K	$2.21M	$2.14M	$2.04M	$2.16M	$2.13M	$2.11M	$1.90M	$2.17M	$2.13M	$1.94M	$1.00M	$838.75K	$575.00K	$700.00K
# Analysts	1	1	1	1	1	1	1	2	3	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.27%	1.08%	1.09%	1.28%	1.17%	1.03%	0.94%	0.85%	1.02%	1.35%	2.70%	2.55%	3.04%	2.20%

Avidity Biosciences's average Quarter revenue forecast for Dec 23 based on 4 analysts is $12.21M, with a low forecast of $570.98K, and a high forecast of $23.86M. RNA's average Quarter revenue forecast represents a 333.33% increase compared to the company's last Quarter revenue of $2.82M (Sep 23).

Avidity Biosciences EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	1	1	1	1	1	1	1	2	3	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-58.06M	$-52.63M	$-57.60M	$-53.23M	$-44.56M	$-45.98M	$-34.15M	$-38.33M	$-29.10M	$-26.21M	$-23.74M	$-16.16M	$-11.34M	$-10.35M
Avg Forecast	$-4.59M	$-4.26M	$-3.95M	$-3.66M	$-1.67M	$-1.63M	$-1.63M	$-1.63M	$-1.55M	$-4.07M	$-2.63M	$-2.57M	$-12.21M	$-2.21M	$-2.14M	$-2.04M	$-2.16M	$-2.13M	$-2.11M	$-37.46M	$-2.17M	$-2.13M	$-1.94M	$-20.35M	$-838.75K	$-575.00K	$-29.11M
High Forecast	$-4.59M	$-4.26M	$-3.95M	$-3.66M	$-1.67M	$-1.63M	$-1.63M	$-1.63M	$-1.55M	$-3.94M	$-2.63M	$-2.57M	$-570.98K	$-2.21M	$-2.14M	$-2.04M	$-2.16M	$-2.13M	$-2.11M	$-29.97M	$-2.17M	$-2.13M	$-1.94M	$-16.28M	$-838.75K	$-575.00K	$-23.29M
Low Forecast	$-4.59M	$-4.26M	$-3.95M	$-3.66M	$-1.67M	$-1.63M	$-1.63M	$-1.63M	$-1.55M	$-4.20M	$-2.63M	$-2.57M	$-23.86M	$-2.21M	$-2.14M	$-2.04M	$-2.16M	$-2.13M	$-2.11M	$-44.95M	$-2.17M	$-2.13M	$-1.94M	$-24.41M	$-838.75K	$-575.00K	$-34.93M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	26.23%	24.54%	28.17%	24.64%	20.97%	21.76%	0.91%	17.62%	13.69%	13.53%	1.17%	19.27%	19.72%	0.36%

undefined analysts predict RNA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Avidity Biosciences's previous annual EBITDA (undefined) of $NaN.

Avidity Biosciences Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	1	1	1	1	1	1	1	2	3	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-52.36M	$-47.02M	$-47.19M	$-47.72M	$-42.27M	$-44.47M	$-34.01M	$-38.53M	$-29.27M	$-26.34M	$-23.83M	$-16.26M	$-11.41M	$-10.74M
Avg Forecast	$-107.03M	$-107.05M	$-104.14M	$-104.18M	$-110.54M	$-107.09M	$-100.18M	$-97.22M	$-97.58M	$-87.77M	$-93.29M	$-98.22M	$-81.35M	$-93.35M	$-97.85M	$-103.44M	$-109.70M	$-99.79M	$-82.26M	$-38.09M	$-74.58M	$-72.39M	$-76.19M	$-20.44M	$-36.62M	$-39.03M	$-29.69M
High Forecast	$-107.03M	$-107.05M	$-104.14M	$-104.18M	$-110.54M	$-107.09M	$-100.18M	$-97.22M	$-30.49M	$-87.77M	$-93.29M	$-98.22M	$10.54M	$-93.35M	$-97.85M	$-103.44M	$-109.70M	$-99.79M	$-82.26M	$-30.47M	$-74.58M	$-72.39M	$-76.19M	$-16.35M	$-36.62M	$-39.03M	$-23.75M
Low Forecast	$-107.03M	$-107.05M	$-104.14M	$-104.18M	$-110.54M	$-107.09M	$-100.18M	$-97.22M	$-137.22M	$-87.77M	$-93.29M	$-98.22M	$-132.56M	$-93.35M	$-97.85M	$-103.44M	$-109.70M	$-99.79M	$-82.26M	$-45.70M	$-74.58M	$-72.39M	$-76.19M	$-24.53M	$-36.62M	$-39.03M	$-35.63M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.56%	0.48%	0.46%	0.43%	0.42%	0.54%	0.89%	0.52%	0.40%	0.35%	1.17%	0.44%	0.29%	0.36%

Avidity Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RNA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Avidity Biosciences SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	1	1	1	1	1	1	1	2	3	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$13.73M	$12.28M	$12.06M	$10.38M	$10.09M	$8.69M	$8.57M	$7.43M	$6.61M	$6.27M	$5.88M	$4.82M	$3.76M	$2.92M
Avg Forecast	$15.38M	$14.26M	$13.23M	$12.28M	$5.59M	$5.47M	$5.47M	$5.47M	$5.19M	$13.64M	$8.80M	$8.61M	$40.92M	$7.42M	$7.19M	$6.85M	$7.24M	$7.03M	$6.99M	$6.28M	$7.19M	$7.03M	$6.41M	$3.31M	$2.77M	$1.90M	$2.32M
High Forecast	$15.38M	$14.26M	$13.23M	$12.28M	$5.59M	$5.47M	$5.47M	$5.47M	$5.19M	$14.07M	$8.80M	$8.61M	$79.94M	$7.42M	$7.19M	$6.85M	$7.24M	$7.03M	$6.99M	$6.28M	$7.19M	$7.03M	$6.41M	$3.31M	$2.77M	$1.90M	$2.32M
Low Forecast	$15.38M	$14.26M	$13.23M	$12.28M	$5.59M	$5.47M	$5.47M	$5.47M	$5.19M	$13.22M	$8.80M	$8.61M	$1.91M	$7.42M	$7.19M	$6.85M	$7.24M	$7.03M	$6.99M	$6.28M	$7.19M	$7.03M	$6.41M	$3.31M	$2.77M	$1.90M	$2.32M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.85%	1.71%	1.76%	1.43%	1.44%	1.24%	1.36%	1.03%	0.94%	0.98%	1.78%	1.74%	1.98%	1.26%

Avidity Biosciences's average Quarter SG&A projection for Dec 23 is $40.92M, based on 4 Wall Street analysts, with a range of $1.91M to $79.94M. The forecast indicates a 198.07% rise compared to RNA last annual SG&A of $13.73M (Sep 23).

Avidity Biosciences EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	1	1	1	1	1	1	1	2	3	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.71	$-0.66	$-0.67	$-0.83	$-0.80	$-0.89	$-0.70	$-1.63	$-0.68	$-0.70	$-0.64	$-0.43	$-0.30	$-1.25
Avg Forecast	$-0.87	$-0.87	$-0.84	$-0.84	$-0.90	$-0.87	$-0.81	$-0.79	$-0.79	$-0.71	$-0.76	$-0.80	$-0.66	$-0.76	$-0.79	$-0.84	$-0.89	$-0.93	$-0.77	$-0.80	$-0.70	$-0.68	$-0.71	$-0.56	$-0.34	$-0.36	$-0.36
High Forecast	$-0.87	$-0.87	$-0.84	$-0.84	$-0.90	$-0.87	$-0.81	$-0.79	$-0.25	$-0.71	$-0.76	$-0.80	$0.09	$-0.76	$-0.79	$-0.84	$-0.89	$-0.93	$-0.77	$-0.80	$-0.70	$-0.68	$-0.71	$-0.56	$-0.34	$-0.36	$-0.36
Low Forecast	$-0.87	$-0.87	$-0.84	$-0.84	$-0.90	$-0.87	$-0.81	$-0.79	$-1.11	$-0.71	$-0.76	$-0.80	$-1.07	$-0.76	$-0.79	$-0.84	$-0.89	$-0.93	$-0.77	$-0.80	$-0.70	$-0.68	$-0.71	$-0.56	$-0.34	$-0.36	$-0.36
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.94%	0.83%	0.80%	0.93%	0.86%	1.16%	0.88%	2.34%	1.00%	0.98%	1.15%	1.26%	0.82%	3.46%

According to undefined Wall Street analysts, Avidity Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RNA previous annual EPS of $NaN (undefined).

Avidity Biosciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PASG	Passage Bio	$0.67	$6.00	795.52%	Buy
BDTX	Black Diamond Therapeutics	$2.50	$20.00	700.00%	Buy
RLAY	Relay Therapeutics	$4.50	$18.00	300.00%	Buy
ARVN	Arvinas	$19.10	$58.50	206.28%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
IGMS	IGM Biosciences	$7.48	$18.67	149.60%	Buy
PLRX	Pliant Therapeutics	$14.37	$35.50	147.04%	Buy
MLYS	Mineralys Therapeutics	$12.35	$30.00	142.91%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
SWTX	SpringWorks Therapeutics	$37.72	$76.00	101.48%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
RNA	Avidity Biosciences	$32.74	$59.00	80.21%	Buy
AKRO	Akero Therapeutics	$30.61	$50.00	63.35%	Buy
RVMD	Revolution Medicines	$45.16	$65.67	45.42%	Buy
PTGX	Protagonist Therapeutics	$40.69	$57.33	40.89%	Buy

RNA Forecast FAQ

Is Avidity Biosciences a good buy?

Yes, according to 8 Wall Street analysts, Avidity Biosciences (RNA) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of RNA's total ratings.

What is RNA's price target?

Avidity Biosciences (RNA) average price target is $59 with a range of $59 to $59, implying a 85.42% from its last price of $31.82. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Avidity Biosciences stock go up soon?

According to Wall Street analysts' prediction for RNA stock, the company can go up by 85.42% (from the last price of $31.82 to the average price target of $59), up by 85.42% based on the highest stock price target, and up by 85.42% based on the lowest stock price target.

Can Avidity Biosciences stock reach $50?

RNA's average twelve months analyst stock price target of $59 supports the claim that Avidity Biosciences can reach $50 in the near future.

What are Avidity Biosciences's analysts' financial forecasts?

Avidity Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6.57M (high $6.57M, low $6.57M), average EBITDA is $-6.567M (high $-6.567M, low $-6.567M), average net income is $-415M (high $-415M, low $-415M), average SG&A $22.01M (high $22.01M, low $22.01M), and average EPS is $-3.364 (high $-3.364, low $-3.364). RNA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $16.46M (high $16.46M, low $16.46M), average EBITDA is $-16.458M (high $-16.458M, low $-16.458M), average net income is $-422M (high $-422M, low $-422M), average SG&A $55.15M (high $55.15M, low $55.15M), and average EPS is $-3.424 (high $-3.424, low $-3.424).

Did the RNA's actual financial results beat the analysts' financial forecasts?

Based on Avidity Biosciences's last annual report (Dec 2023), the company's revenue was $9.56M, which missed the average analysts forecast of $18.61M by -48.64%. Apple's EBITDA was $-236M, beating the average prediction of $-18.614M by 1165.69%. The company's net income was $-212M, missing the average estimation of $-376M by -43.56%. Apple's SG&A was $54.19M, missing the average forecast of $62.38M by -13.13%. Lastly, the company's EPS was $-2.91, missing the average prediction of $-3.048 by -4.51%. In terms of the last quarterly report (Sep 2023), Avidity Biosciences's revenue was $2.82M, beating the average analysts' forecast of $2.21M by 27.30%. The company's EBITDA was $-58.059M, beating the average prediction of $-2.214M by 2522.83%. Avidity Biosciences's net income was $-52.358M, missing the average estimation of $-93.354M by -43.91%. The company's SG&A was $13.73M, beating the average forecast of $7.42M by 85.07%. Lastly, the company's EPS was $-0.71, missing the average prediction of $-0.757 by -6.17%